Details of a Researcher - Adachi, Takeya

Papers - Adachi, Takeya

Division display 21 - 40 of about 57 ／ All the affair displays >>

Erythema multiforme following vaccination for SARS-CoV-2: Report of a case and review of the literature - Secondary Publication.

Yuki Kobyashi, Takeya Adachi, Hiroki Arakawa, Mie Takeuchi, Toyoko Inazumi

The Australasian journal of dermatology 63 ( 4 ) e381-e385 2022.11

Access to Document (DOI)

A case of refractory leg ulcers caused by micro-arteriovenous fistula: Potential utility of ultrasonography in the diagnosis.

Akihiro Miyagawa, Takeya Adachi, Hiroki Arakawa, Mariko Hamada, Yoshinobu Akiyama, Toyoko Inazumi

The Journal of dermatology 49 ( 10 ) e389-e390 2022.10

Access to Document (DOI)

【デジタルヘルスを取り巻く法と倫理】地域開発型イノベーション・エコシステム構築に資する国内外の若手研究者ニーズ実態調査研究

足立剛也, 武内歩, 早野元詞, 黒田垂歩

Journal of Internet of Medical Things ((一社)IoMT学会) 5 ( 1 ) 34 - 40 2022.10

ISSN 2433-9571

世界に伍するイノベーション・エコシステムの構築には,テクノロジーと研究者を含む人材の集積基盤が必須となる.そこで,海外で活躍する日本人研究者6,000人をつなぐ海外日本人研究者ネットワーク(UJA)等の協力のもと,国内だけでなく海外在住の日本人研究者も対象とし,異動先の研究・居住環境やスタートアップのニーズに関する実態調査を行った.結果,海外在住若手研究者は,立地よりも予算支援が大きいことが明らかとなった.また,研究環境だけでなく,家族・パートナーを含めた居住環境の整備,オープンイノベーション推進に関する人的・財政的支援は,研究者を誘致する上で,さらに考慮すべき項目となってくると推測された.(著者抄録)

Palpation Robot System - Reproduction Method by Deep Neural Network of Skin Palpation Judgment Focusing on Softness Classification-

2022.09

Access to Document (DOI)

Six years' accomplishment of the Initiative on Rare and Undiagnosed Diseases: nationwide project in Japan to discover causes, mechanisms, and cures.

Yuji Takahashi, Hidetoshi Date, Hideki Oi, Takeya Adachi, Noriaki Imanishi, En Kimura, Hotake Takizawa, Shinji Kosugi, Naomichi Matsumoto, Kenjiro Kosaki, Yoichi Matsubara, Hidehiro Mizusawa

Journal of human genetics 67 ( 9 ) 505 - 513 2022.09

The identification of causative genetic variants for hereditary diseases has revolutionized clinical medicine and an extensive collaborative framework with international cooperation has become a global trend to understand rare disorders. The Initiative on Rare and Undiagnosed Diseases (IRUD) was established in Japan to provide accurate diagnosis, discover causes, and ultimately provide cures for rare and undiagnosed diseases. The fundamental IRUD system consists of three pillars: IRUD diagnostic coordination, analysis centers (IRUD-ACs), and a data center (IRUD-DC). IRUD diagnostic coordination consists of clinical centers (IRUD-CLs) and clinical specialty subgroups (IRUD-CSSs). In addition, the IRUD coordinating center (IRUD-CC) manages the entire IRUD system and temporarily operates the IRUD resource center (IRUD-RC). By the end of March 2021, 6301 pedigrees consisting of 18,136 individuals were registered in the IRUD. The whole-exome sequencing method was completed in 5136 pedigrees, and a final diagnosis was established in 2247 pedigrees (43.8%). The total number of aberrated genes and pathogenic variants was 657 and 1718, among which 1113 (64.8%) were novel. In addition, 39 novel disease entities or phenotypes with 41 aberrated genes were identified. The 6-year endeavor of IRUD has been an overwhelming success, establishing an all-Japan comprehensive diagnostic and research system covering all geographic areas and clinical specialties/subspecialties. IRUD has accurately diagnosed diseases, identified novel aberrated genes or disease entities, discovered many candidate genes, and enriched phenotypic and pathogenic variant databases. Further promotion of the IRUD is essential for determining causes and developing cures for rare and undiagnosed diseases.

Access to Document (DOI)

患者教育・チーム医療・医療連携多職種が集うリカレント教育の重要性アレルギー診療ITC教育(出前授業による教育の機会創出事業)活動と展望

正木克宜, 坂下雅文, 小川靖, 猪俣武範, 神尾敬子, 佐藤さくら, 中島沙恵子, 福島敦樹, 森田英明, 神崎晶, 福永興壱, 石塚全, 尾山徳孝, 木戸口正典, 安冨素子, 足立剛也

アレルギー ((一社)日本アレルギー学会) 71 ( 6-7 ) 839 - 839 2022.08

ISSN 0021-4884

患者教育・チーム医療・医療連携多職種が集うリカレント教育の重要性アレルギー診療ITC教育(出前授業による教育の機会創出事業)活動と展望

アレルギー ((一社)日本アレルギー学会) 71 ( 6-7 ) 839 - 839 2022.08

ISSN 0021-4884

アレルギー診療教育のための多職種・学際的学習共同体の形成(Formation of an interdisciplinary learning community for multidisciplinary allergology education)

正木克宜, 春田淳志, 百武美沙, 坂下雅文, 小川靖, 猪俣武範, 神尾敬子, 佐藤さくら, 中島沙恵子, 福島敦樹, 森田英明, 神崎晶, 福永興壱, 石塚全, 尾山徳孝, 木戸口正典, 安冨素子, 足立剛也, 免疫アレルギー疾患研究10か年戦略次世代タスクフォース

医学教育 ((一社)日本医学教育学会) 53 ( Suppl. ) 137 - 137 2022.07

ISSN 0386-9644

アレルギー診療教育のための多職種・学際的学習共同体の形成(Formation of an interdisciplinary learning community for multidisciplinary allergology education)

医学教育 ((一社)日本医学教育学会) 53 ( Suppl. ) 137 - 137 2022.07

ISSN 0386-9644

Prevalence of Comorbidity between Dry Eye and Allergic Conjunctivitis: A Systematic Review and Meta-Analysis.

Yasutsugu Akasaki, Takenori Inomata, Jaemyoung Sung, Masahiro Nakamura, Koji Kitazawa, Kendrick Co Shih, Takeya Adachi, Yuichi Okumura, Kenta Fujio, Ken Nagino, Akie Midorikawa-Inomata, Mizu Kuwahara, Kunihiko Hirosawa, Tianxiang Huang, Yuki Morooka, Hurramhon Shokirova, Atsuko Eguchi, Akira Murakami

Journal of clinical medicine 11 ( 13 ) 2022.06

This systematic review aimed to determine the comorbid dry eye (DE) and allergic conjunctivitis (AC) prevalence. We searched PubMed and EMBASE for articles published until 22 March 2022, combining the terms "(dry eye OR keratoconjunctivitis sicca) AND allergic conjunctivitis." Study-specific estimates (DE and AC incidence rates among patients with AC and DE, respectively) were combined using the one-group meta-analysis in a random-effects model. The initial search yielded 700 studies. Five articles reporting AC incidence among individuals with DE and six articles reporting DE incidence among individuals with AC were included in the qualitative synthesis. In these nine articles, the total sample size was 7254 patients. The DE incidence among individuals with AC was 0.9-97.5%; the AC incidence among individuals with DE was 6.2-38.0%. One-group meta-analysis using a random-effects model showed that 47.2% (95% confidence interval: 0.165-0.779; 320/1932 cases) of patients with AC had comorbid DE and 17.8% (95% confidence interval: 0.120-0.236; 793/4855 cases) of patients with DE had comorbid AC, as defined by each article. Complimentary screening and treatment for patients with DE and AC may improve long-term outcomes and prevent chronic ocular damage in highly susceptible populations.

Access to Document (DOI)

Research impact analysis of international funding agencies in the realm of allergy and immunology.

Takeya Adachi, Yasushi Ogawa, Tamami Fukushi, Kei Ito, Amane Koizumi, Masashi Shirabe, Masako Toriya, Jun Hirako, Takenori Inomata, Katsunori Masaki, Ryohei Sasano, Sakura Sato, Keigo Kainuma, Masaki Futamura, Keiko Kan-O, Yosuke Kurashima, Saeko Nakajima, Masafumi Sakashita, Hideaki Morita, Aikichi Iwamoto, Sankei Nishima, Mayumi Tamari, Hajime Iizuka

Allergy 77 ( 5 ) 1602 - 1606 2022.02

Access to Document (DOI)

新型コロナウィルスワクチン接種後に出現した多形紅斑-DLST結果を含めた症例報告

小林由季, 足立剛也, 新川宏樹, 稲積豊子

日本皮膚科学会雑誌 ((公社)日本皮膚科学会) 132 ( 1 ) 69 - 73 2022.01

ISSN 0021-499X

77歳男性。新型コロナウィルスワクチン(コミナティ筋注)2回目接種2日後より紅斑が出現し、全身へ拡大した。接種3週間後の初診時、躯幹四肢に環状で6cm大までの融合傾向のある浮腫状暗紅色斑が散在し、一部標的様を呈した。経過・検査所見より、コミナティ筋注接種後の多形紅斑と診断した。新型コロナウィルスワクチン接種後の多形紅斑の報告はまだ少なく、今後ワクチンのさらなる普及に伴い、同様の皮疹を呈する例の増加も予想される。陰性対照も含め提出したコミナティ筋注のDLST結果及び文献的考察を加え報告する。(著者抄録)

Evaluation of adrenaline auto-injector prescription profiles: A population-based, retrospective cohort study within the National Insurance Claims Database of Japan

Sakura Sato, Keigo Kainuma, Tatsuya Noda, Motohiro Ebisawa, Masaki Futamura, Tomoaki Imamura, Akihiro Miyagawa, Saeko Nakajima, Yasushi Ogawa, Takenori Inomata, Keiko Kan-o, Yosuke Kurashima, Katsunori Masaki, Tomoya Myojin, Yuichi Nishioka, Masafumi Sakashita, Mayumi Tamari, Hideaki Morita, Takeya Adachi

Allergology International (Elsevier BV) 71 ( 3 ) 354 - 361 2022

ISSN 13238930

BACKGROUND: Adrenaline is the first-line medication for managing anaphylaxis. A better understanding of prescription trends for adrenaline auto-injectors (AAIs) is important to improving patient care as well as information on health education interventions and medical guidelines. However, it has been difficult to gather comprehensive data in a sustainable manner. Thus, we aimed to investigate trends in AAI prescriptions in Japan. METHODS: We searched the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), a unique and comprehensive database of health insurance claims, and investigated prescriptions for AAIs for all ages (April 2017 to March 2018). We assessed the annual number of prescriptions per person as well as prescription rates per 100,000 population per year by age, sex, and geographic region. RESULTS: A total of 88,039 subjects (56,109 males, 31,930 female) and 116,758 devices (1.33 AAIs per patient per year) were prescribed AAIs at least once a year for all ages. The prescription rate for AAIs was 69.5 per 100,000 population-years. Patients aged 0-9 years were prescribed AAIs at the rate of 278.9 per 100,000 population-years. Patients aged 0-19 years were 6.4 times more likely to be prescribed AAIs than those over 20 years of age. Males were more frequently prescribed AAIs than females in all age groups, except for those aged 20-24 years. We also evaluated differences in prescription rates by geographic region. CONCLUSIONS: This comprehensive evaluation revealed trends in AAI prescriptions, thus helping develop preventive strategies with respect to anaphylaxis in Japan.

Access to Document (DOI)

A case of aggressive and protuberant nodular fasciitis on the finger with repeated contact.

Hiroki Arakawa, Takeya Adachi, Akihiro Miyagawa, Keiko Miura, Kentaro Ogata, Toyoko Inazumi

The Australasian journal of dermatology (Wiley) 63 ( 1 ) e102-e103 2021.12

Access to Document (DOI)

Plasmapheresis as a promising treatment option in apalutamide-associated toxic epidermal necrolysis.

Akihiro Miyagawa, Takeya Adachi, Yuki Kobayashi, Saeko Takamiyagi, Hiroki Arakawa, Koji Futatsugi, Toyoko Inazumi

The Journal of dermatology (Wiley) 49 ( 3 ) e102-e103 2021.11

Access to Document (DOI)

A case of vancomycin‐induced linear IgA bullous dermatosis with toxic epidermal necrolysis‐like symptoms: Palmoplantar eruptions as a possible risk marker

Motoki Adachi, Takeya Adachi, Masaki Yokota, Chika Ichimura, Kenji Yoshida, Ken Ishii, Akira Ishiko

The Journal of Dermatology (Wiley) 48 ( 12 ) e610-e611 2021.09

Access to Document (DOI)

【好中球が関与する皮膚病】下腿紫斑が先行し,フルニエ壊疽が合併したseptic vasculitis

宮川明大, 足立剛也, 高宮城冴子, 新川宏樹, 小幡祥子, 稲積豊子

皮膚病診療 ((株)協和企画) 43 ( 5 ) 444 - 447 2021.05

ISSN 0387-7531

First case of lenvatinib-induced pyoderma gangrenosum: Possible management with dose reduction.

Akihiro Miyagawa, Takeya Adachi, Saeko Takamiyagi, Hiroki Arakawa, Misako Matsushita, Toyoko Inazumi

The Journal of dermatology 48 ( 5 ) e221-e222 2021.03

Access to Document (DOI)

Strategic Outlook toward 2030: Japan's research for allergy and immunology - Secondary publication.

Takeya Adachi, Keigo Kainuma, Koichiro Asano, Masayuki Amagai, Hiroyuki Arai, Ken J Ishii, Komei Ito, Eiichi Uchio, Motohiro Ebisawa, Mitsuhiro Okano, Kenji Kabashima, Kenji Kondo, Satoshi Konno, Hidehisa Saeki, Mariko Sonobe, Mizuho Nagao, Nobuyuki Hizawa, Atsuki Fukushima, Shigeharu Fujieda, Kenji Matsumoto, Hideaki Morita, Kazuhiko Yamamoto, Akemi Yoshimoto, Mayumi Tamari

Allergology international : official journal of the Japanese Society of Allergology (Elsevier {BV}) 69 ( 4 ) 561 - 570 2020.10

ISSN 13238930

Strategic Outlook toward 2030: Japan's Research for Allergy and Immunology (Strategy 2030) is the national research strategy based on Japan's Basic Law on Measures Against Allergic Diseases, a first of its kind worldwide. This strategy was established by a multi-disciplinary committee consisting of administrators of the Ministry of Health, Labour and Welfare of Japan, young and senior experts from various research societies and associations, and representatives of patient and public groups. Whereas the issues of transition, integration, and international collaboration have yet to be solved in this research realm in Japan, identification of unmet needs, digitization of information and transparent procedures, and strategic planning for complex problems (a process dubbed MIERUKA by the Toyota Way) are crucial to share and tackle the same vision and goals. The committee developed three specific actions focusing on preemptive treatment, interdisciplinarity and internationality, and life stage. The real success of Strategy 2030 is made by the spontaneous contributions of doctors, dentists, veterinarians, and other medical professionals; basic and clinical research scientists, research supporters, and pharmaceutical/medical device companies; manufacturers of food, healthcare, and home appliances; and patients, their families, and the public. The hope is to establish a stable society in which people can live long, healthy lives, as free as possible from allergic and immunological diseases, at each individual life stage. This article is based on a Japanese review first reported in Arerugi, introduces the developmental process and details of Strategy 2030.

Access to Document (DOI)

Strategic outlook toward 2030: Japan's research for allergy and immunology

Adachi T., Kainuma K., Asano K., Amagai M., Arai H., Ishii K.J., Ito K., Uchio E., Ebisawa M., Okano M., Kabashima K., Kondo K., Konno S., Saeki H., Sonobe M., Nagao M., Hizawa N., Fukushima A., Fujieda S., Matsumoto K., Morita H., Yamamoto K., Yoshimoto A., Tamari M.

Japanese Journal of Allergology (Japanese Journal of Allergology) 69 ( 1 ) 23 - 33 2020

ISSN 00214884

Access to Document (DOI)

　 Previous page - Next page 　